HIV
New HIV pill for UK
May 29, 2013Sales and Marketing Gilead, HIV, stribild
Gilead Sciences has launched Stribild, a once-daily single tablet regimen to combat HIV – the virus which causes AIDS – …
ViiV HIV drug boost
February 18, 2013Sales and Marketing Dolutegravir, GSK, HIV, ViiV
ViiV Healthcare has received a boost with the news that the FDA is to give a priority review to its …
AbbVie splits from Abbott
January 7, 2013Sales and Marketing AbbVie, Abbott, HIV, Humira
AbbVie, the new $18 billion biopharma company which includes many of Abbott’s most high profile products, has finally launched. Abbott …
Shionogi and ViiV strike new HIV deal
October 30, 2012Research and Development, Sales and Marketing Atripla, Dolutegravir, HIV, Shionogi, ViiV
HIV specialist firm ViiV Healthcare has announced a new deal with Japan’s Shionogi on a promising new treatment. ViiV Healthcare …
NHS under fire for ‘misdiagnosis’
October 5, 2012Sales and Marketing BHIVA, HIV, NHS
Patients with HIV infections are going unnoticed by the NHS while those with rare diseases are often being misdiagnosed. These …
New quad HIV pill passed by FDA
September 2, 2012Sales and Marketing FDA, Gilead, HIV, stribild
Gilead’s four-in-one anti-HIV once-daily pill Stribild has been given the green light by the FDA for adults who have not …
Pharma R&D model no help to developing countries
May 22, 2012Research and Development, Sales and Marketing HIV, MSF, Médecins Sans Frontières, R&D
Médecins Sans Frontières is urging health ministers around the world to create an ‘R&D Convention’ to ensure that pharma helps …
New Quad HIV pill on track for FDA approval
May 14, 2012Research and Development, Sales and Marketing BMS, Compera, FDA, Gilead, HIV, The Quad
Gilead Sciences’ four-in-one HIV pill has been given the thumbs up by an FDA advisory group. The US regulator is …
Novartis Indian patent battle nears conclusion
March 7, 2012Sales and Marketing Glivec, HIV, India, Novartis, patents
A long-running battle over the patent of cancer treatment Glivec in India is about to reach its dramatic climax.India’s Supreme …
Lonza forges joint venture with South Africa for HIV drugs
February 13, 2012Manufacturing and Production HIV, Lonza, South Africa
Swiss contract manufacturer Lonza has signed a joint venture agreement with the government of South Africa that could significantly reduce …
Doctors decry cost-cutting in HIV treatment
November 2, 2011Sales and Marketing HIV, NHS, Reyataz
Doctors in London are opposing a decision to switch HIV patients to a cheaper drug, saying it could harm patients. …
Boehringer signs away HIV rights to focus on hep C
October 7, 2011Research and Development Boehringer, Gilead, HIV, hepatitis C
Boehringer Ingelheim has signed a deal giving Gilead Sciences exclusive worldwide rights to a major part of its HIV portfolio. …
Once daily Viramune set for approval in Europe
August 1, 2011Sales and Marketing Boehringer Ingelheim, HIV
European regulators have recommended the approval of a new, once-daily form of Boehringer Ingelheim’s HIV treatment Viramune. Viramune (nevirapine) has …
HIV drug Prezista recalled on TBA contamination
May 17, 2011Manufacturing and Production HIV, Johnson & Johnson, Prezista, manufacturing and production, recalls
Johnson & Johnson has recalled 11,700 bottles of its HIV treatment Prezista after consumer reports of a mouldy smell caused …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
